What to Eat During Cancer Treatment | American Cancer Society
Independent Publishers Group
Independent Publishers Group
Hydroxyurea dose escalation to MTD with dose optimisation significantly improved clinical responses and treatment outcomes, without increasing toxicities in children with sickle cell anaemia in…
Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is a large prospective open-label, non-randomised trial of hydroxyurea (hydroxycarbamide) for children aged 1–10 years with sickle cell…
Your diet, including alcohol, can impact the body’s microbiome. Here, researcher Carrie Daniel-MacDougall, Ph.D., explains how alcohol affects the microbiome and the healthiest way to…
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
An abstract is unavailable.
The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars. To…
Here we summarize a presentation by Sham Mailankody from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on the…
Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.
Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial.